EGFR mutation or overexpression leads to malignant progression in many cancer types.510 In PCa, increased expression of EGFR correlates with a high Gleason score and advanced stage disease,511 and activation of EGFR promotes metastatic progression and recurrence.512 EGFR inhibitors such as gefitinib (a small-molecule compound) and cetuximab (a monoclonal antibody) have been widely used in metastatic colorectal cancer and non-small cell lung cancer. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.